Roth Capital Predicts Beyond Air FY2029 Earnings

Beyond Air, Inc. (NASDAQ:XAIR) – Roth Capital issued their FY2029 EPS estimates for Beyond Air in a report released on Tuesday, February 11th. Roth Capital analyst J. Wittes forecasts that the company will earn $0.06 per share for the year. The consensus estimate for Beyond Air’s current full-year earnings is ($0.87) per share.

Beyond Air Stock Performance

XAIR opened at $0.39 on Thursday. The stock has a market capitalization of $29.58 million, a price-to-earnings ratio of -0.28 and a beta of -0.15. The company has a fifty day moving average of $0.41 and a 200 day moving average of $0.43. Beyond Air has a fifty-two week low of $0.30 and a fifty-two week high of $2.12. The company has a debt-to-equity ratio of 0.37, a quick ratio of 5.38 and a current ratio of 5.76.

Beyond Air (NASDAQ:XAIR) last posted its earnings results on Monday, February 10th. The company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.09. Beyond Air had a negative net margin of 2,369.17% and a negative return on equity of 227.29%. During the same quarter in the previous year, the business earned ($0.50) earnings per share.

Hedge Funds Weigh In On Beyond Air

Several institutional investors have recently bought and sold shares of XAIR. Soros Fund Management LLC purchased a new position in Beyond Air during the third quarter valued at $573,000. Baldwin Wealth Partners LLC MA grew its stake in Beyond Air by 721.3% during the fourth quarter. Baldwin Wealth Partners LLC MA now owns 308,000 shares of the company’s stock valued at $110,000 after acquiring an additional 270,500 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in Beyond Air by 81.0% during the fourth quarter. Geode Capital Management LLC now owns 562,713 shares of the company’s stock valued at $202,000 after acquiring an additional 251,823 shares in the last quarter. 31.50% of the stock is owned by hedge funds and other institutional investors.

Beyond Air Company Profile

Beyond Air, Inc operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn.